Pfizer and Viking Therapeutics Underperform in 2025, Trading Below $40
Written by Emily J. Thompson, Senior Investment Analyst
Source: Fool
- Pfizer Stock Analysis: Pfizer's current share price is $26, and despite poor performance over the past three years, the company is conducting late-stage clinical trials for its promising cancer drug PF-4404, which is expected to pave the way for financial improvement and help overcome patent cliffs.
- New Drug Development Progress: Pfizer's significant strides in the weight management market with the acquisition of mid-stage asset MET-097i highlight the company's strategic diversification in its product pipeline, which is crucial for future growth.
- Viking Therapeutics Risks and Opportunities: Viking Therapeutics, trading at $34 per share, is a clinical-stage biotech with no market products, but its leading candidate VK2735 shows great potential in weight loss, currently undergoing phase 3 studies, and could significantly boost the stock price if successful.
- Clinical Research Strategy: Viking's approach to VK2735 includes investigating both subcutaneous and oral formulations to address weight regain issues post-treatment, and if solid clinical progress is made in the next two years, the stock could see substantial gains.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.860
Low
24.00
Averages
28.56
High
35.00
Current: 25.860
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's Revenue Rebound Potential is Significant
- Revenue Decline: Pfizer projects its 2025 revenue to be between $61 billion and $64 billion, significantly lower than the record-breaking over $100 billion in 2022, indicating challenges in revenue recovery post-COVID-19.
- Shift in Drug Development Focus: The company has struggled to prioritize other drug developments after the success of its COVID-19 vaccine, leading to slow progress in its drug pipeline and impacting overall market competitiveness.
- New Drug Market Potential: Pfizer aims to launch several new billion-dollar oncology drugs by 2030 and has entered a weight-loss drug market through its $10 billion acquisition of Metsera, which could be worth over $150 billion annually, showcasing significant future growth potential.
- Acquisitions Create New Opportunities: The acquisitions of Arena Pharmaceuticals in 2022 and Seagen for $43 billion in 2023 inject new prospects into Pfizer's pipeline, although these new drugs will not complete testing until after 2030, providing hope for future growth despite current challenges.
Continue Reading
Analysis of High-Yield Stock Investment Opportunities
- Stable Income from Realty Income: Realty Income boasts a dividend yield of 5.3% and has increased its monthly dividend for 30 consecutive years, reflecting its solid investment-grade balance sheet and conservative management approach, making it a cornerstone investment for conservative investors.
- Procter & Gamble's Dividend King Status: As one of the largest consumer goods companies globally, Procter & Gamble faces volume declines due to economic slowdowns, yet its 2.8% dividend yield and over 60 years of annual dividend increases make it attractive in uncertain markets.
- Pfizer's Turnaround Challenges: Pfizer offers a high dividend yield of 6.7%, but investor sentiment is low due to patent expirations and challenges in drug development; however, the company is actively acquiring promising drug pipelines to navigate current setbacks.
- Diverse Investment Options: Realty Income, Procter & Gamble, and Pfizer each present unique characteristics and yields above market averages, requiring investors to align their investment goals with these opportunities.
Continue Reading